Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort.
Adult
Aged
Albuminuria
/ etiology
Blood Pressure
Cardiovascular Diseases
/ etiology
Cholesterol, LDL
/ blood
Diabetes Mellitus, Type 2
/ blood
Diabetic Angiopathies
/ etiology
Diabetic Cardiomyopathies
/ etiology
Female
Humans
Insulin Resistance
Kidney
/ physiopathology
Latent Class Analysis
Male
Middle Aged
Netherlands
/ epidemiology
Prospective Studies
Risk Factors
Triglycerides
/ blood
cardiovascular risk
mediation analysis
risk factors
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
01
2019
revised:
17
04
2019
accepted:
30
04
2019
pubmed:
8
5
2019
medline:
17
9
2020
entrez:
8
5
2019
Statut:
ppublish
Résumé
To quantify the magnitude and specific contributions of known cardiovascular risk factors leading to higher cardiovascular risk and all-cause mortality caused by type 2 diabetes (T2D). Mediation analysis was performed to assess the relative contributions of known classical risk factors for vascular disease in T2D (insulin resistance, systolic blood pressure, renal function, LDL-cholesterol, triglycerides and micro-albuminuria), and what proportion of the effect of T2D on cardiovascular events and all-cause mortality these factors mediate in the Second Manifestations of ARTerial disease (SMART) cohort consisting of 1910 T2D patients. Only 35% (95% CI 15-71%) of the excess cardiovascular risk caused by T2D is mediated by the classical cardiovascular risk factors. The largest mediated effect was through insulin resistance [proportion of mediated effect (PME) 18%, 95% CI 3-37%], followed by elevated triglycerides (PME 8%, 95% CI 4-14%) and micro-albuminuria (PME 7%, 95% CI 3-17%). Only 42% (95% CI 18-73%) of the excess mortality risk was mediated by the classical risk factors considered. The largest mediated effect was by micro-albuminuria (PME 18%, 95% CI 10-29%) followed by insulin resistance (PME 15%, 95% CI 1-33%). A substantial amount of the increased cardiovascular risk and all-cause mortality caused by T2D cannot be explained by traditional vascular risk factors. Future research should focus on identifying non-classical pathways that might further explain the increased cardiovascular and mortality risk caused by T2D.
Identifiants
pubmed: 31062479
doi: 10.1111/dom.13759
pmc: PMC6767388
doi:
Substances chimiques
Cholesterol, LDL
0
Triglycerides
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1935-1943Investigateurs
R van Petersen
(R)
B G F Dinther
(BGF)
A Algra
(A)
Y van der Graaf
(Y)
D E Grobbee
(DE)
G E H M Rutten
(GEHM)
F L J Visseren
(FLJ)
G J de Borst
(GJ)
L J Kappelle
(LJ)
T Leiner
(T)
H M Nathoe
(HM)
Informations de copyright
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Eur Heart J. 2008 Dec;29(24):2959-71
pubmed: 18775919
Am J Epidemiol. 2012 Aug 1;176(3):190-5
pubmed: 22781427
N Engl J Med. 1997 Apr 3;336(14):973-9
pubmed: 9077376
BMJ. 2013 Jul 29;347:f4533
pubmed: 23900314
Diabetes Care. 1999 Apr;22(4):562-8
pubmed: 10189532
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Am J Epidemiol. 2014 Feb 15;179(4):513-8
pubmed: 24264291
Diabetes. 1998 Feb;47(2):290-3
pubmed: 9519730
Diabetes Obes Metab. 2019 Aug;21(8):1935-1943
pubmed: 31062479
Am J Cardiol. 1999 Jul 8;84(1A):37J-41J
pubmed: 10418858
Diabetes Obes Metab. 2016 Nov;18(11):1120-1127
pubmed: 27337598
Diabetologia. 2008 Apr;51(4):527-39
pubmed: 18239908
Lancet Diabetes Endocrinol. 2015 May;3(5):356-66
pubmed: 25791290
World J Cardiol. 2012 Apr 26;4(4):90-102
pubmed: 22558488
Metabolism. 2005 Mar;54(3):345-50
pubmed: 15736112
Circulation. 1998 Aug 25;98(8):731-3
pubmed: 9727541
Int J Obes (Lond). 2008 May;32 Suppl 2:S21-4
pubmed: 18469836
Circulation. 2005 Nov 15;112(20):3066-72
pubmed: 16275870
Diabetes Care. 2006 Feb;29(2):329-33
pubmed: 16443882
Clin Biochem. 2004 Sep;37(9):785-90
pubmed: 15329317
Heart. 2001 Jan;85(1):87-91
pubmed: 11119472
Diabetes Care. 1999 Sep;22(9):1543-8
pubmed: 10480523
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Endocr Rev. 2004 Feb;25(1):153-75
pubmed: 14769830
Ann Intern Med. 2000 Jul 18;133(2):81-91
pubmed: 10896647
Am J Med. 2006 Oct;119(10):812-9
pubmed: 17000207
N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
Arch Intern Med. 1997 Jul 14;157(13):1413-8
pubmed: 9224218
Diabetes Care. 2002 Jul;25(7):1135-41
pubmed: 12087010
Eur J Epidemiol. 1999 Oct;15(9):773-81
pubmed: 10608355